DaVita Inc.
DVA · Price history
Price at last available close
$183.93
+$8.74 (+4.99%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About DaVita Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD).
How they make money
DaVita generates revenue primarily by providing dialysis services to patients suffering from chronic kidney failure or end-stage renal disease. The company operates through a network of outpatient dialysis centers and provides integrated kidney care services, receiving payments from government programs like Medicare and Medicaid, as well as private commercial health insurance plans.
Products & services
Outpatient dialysis services, integrated kidney care (IKC) disease management, and administrative services for kidney care centers.
Brands & revenue mix
The primary brand under which the company provides its core dialysis and integrated care services.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Disclosed major customers
- Centers for Medicare & Medicaid Services (CMS)Source
Customer concentration
A significant portion of the company's revenue is derived from government-sponsored healthcare programs, primarily Medicare and Medicaid, as disclosed in the 2025 annual report.
Suppliers, materials & equipment
- Medical equipment and pharmaceutical manufacturers — The company relies on various unnamed suppliers for dialysis machines, dialyzers, and pharmaceutical products used in patient treatment.Source
Competitors
- Fresenius Medical Care — A major global provider of dialysis services and products that competes directly with DaVita in the U.S. and international markets.Source
Strengths
Sources
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
41
Weak
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
45
Weak
Financial Strength
34
Business Quality / Moat
62
Management
39
Growth Quality
32
Risk / Durability
70
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
62
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
63/100
Building Historical Record
Model Score 63/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Elevated debt risk
- •Repurchase headline · Oct 9, 2026
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for DVA
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can DVA maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is DVA's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is DVA's debt load manageable relative to cash generation, interest costs and upcoming maturities?
Essential Investment Snapshot
Wall Street Score
41
Opportunity Score
62
Market Cap
$11.73B
P/E Ratio
15.0
EPS
$11.63
52-Week High
$247.49
52-Week Low
$101.00
Beta
0.83
Intrinsic Value
$227.40
Analyst Target
$222.00
Shares Outstanding
88.1M
Total Revenue
$14.01B
Total Debt
$10.78B
Dividend
No current dividend
Liquidation Value / Share
$12.25
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for DVA
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Elevated debt risk
Negative shareholder equity • Total debt is at least one year of revenue • Cash covers less than 20% of total debt
Repurchase headline · Oct 9, 2026
DaVita: After A 25% Drop, The Buyback Machine Is Cheap Again — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
Seeking AlphaCommunity Sentiment
0 active · 0 total callsNo personal call yet on DVA.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Extensive network of outpatient dialysis centers.
- +Leadership in clinical quality and kidney care innovation.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Debt risk (elevated): Negative shareholder equity.
- −Total debt is at least one year of revenue.
- −Cash covers less than 20% of total debt.
- −Dependence on government reimbursement rates.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
40
Sep 21, 2026
Change
+1.6
points
Current Score
41
Oct 1, 2026
Category Changes
DVA increased 1.6 points because Capital improved by 3 points, Valuation improved by 5.7 points.
Positive Contributors
- + Capital improved by 3 points
- + Valuation improved by 5.7 points
Projected Score
Projected Score
49
Projected Change
+8.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 8.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$183.93
Model Intrinsic Value
$227.40
Difference
−$43.47
-19.1% vs IV
Margin of Safety
19.1%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.01B | $13.64B | $12.82B | $12.14B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $9.66B | $9.96B | $8.60B | $8.32B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $4.35B | $3.68B | $4.22B | $3.82B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $0.00 | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $1.73B | $1.67B | $1.54B | $1.47B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $2.24B | $1.67B | $2.13B | $2.22B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $2.76B | $2.64B | $2.72B | $2.32B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $2.11B | $2.01B | $2.09B | $1.60B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $560.1M | $549.7M | $470.5M | $398.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $1.47B | $1.35B | $1.53B | $1.18B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $303.3M | $293.1M | $279.7M | $220.1M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $847.5M | $746.8M | $936.3M | $691.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $11.63 | $9.72 | $11.02 | $7.62 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 64.78M | 86.10M | 84.99M | 90.79M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 66.09M | 88.10M | 87.27M | 93.18M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$3.55B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$4.02
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-15.9%
Cash Change
-5.6%
Margin Change
+1.6 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels, net income margin. Pressure indicators included cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 5.2%. EPS increased 55.8%. Cash declined 5.6%. Total debt declined 15.9%. Net income margin improved by 1.6 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
34
Smart Money
34
Number of Gurus
2
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
6 historical recordsHistorical Score Chart
3 of 6 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - Care FacilitiesNews
DaVita Brings Preventive Health Screenings Into Communities to Help Identify Hidden Health Risks
DaVita HealthCare (DVA) Falls More Steeply Than Broader Market: What Investors Need to Know
18,685 DaVita Inc. $DVA Shares Acquired by Counterpoint Mutual Funds LLC
DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care
Rumor Mill · DVA
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial